The recent Alzheimer’s and Parkinson’s Disease Conference (ADPD) demonstrated that it is an exciting time for drug development in Parkinson’s disease. Parkinson’s disease is being redefined by alpha synuclein biology,…
Read More
NEW YORK–(BUSINESS WIRE)–Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, today announced the first collaboration in the Koneksa Academic Partnership Program for Parkinson’s Disease (KAPP-PD) to incorporate its Neuroscience...
Read More
At the recent CNS Summit – an annual gathering of R&D life science leaders that has taken place since 2009 – Koneksa was proud to sit down with some of…
Using data from digital health technologies is making it possible to measure the performance of investigational treatments more rapidly, completely, and accurately than ever before. What’s a digital biomarker?Biomarkers are,…
While the breakneck pace of technological innovation has affected nearly every facet of modern life, the opportunities it has created in clinical research have been game-changing. This has been particularly…
NEW YORK–(BUSINESS WIRE)–Koneksa, a healthcare technology company pioneering digital biomarkers, today announced The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a second research grant to evaluate Parkinson’s...
Read More
NEW YORK–(BUSINESS WIRE)–Koneksa, a healthcare technology company pioneering digital biomarkers, announced today that it has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF)...
Read More
The International Society for CNS Clinical Trials and Methodology (ISCTM) is a multi-disciplinary independent organization devoted to promoting advances in clinical research methods and addressing strategic clinical, regulatory, methodological, and…
